Mounjaro patent ende?

Short answer:
No – the patents covering Mounjaro (tirzepatide) have not yet expired. The drug is still protected by a portfolio of patents that give Eli Lilly exclusive rights to manufacture and sell it in most markets. Generic versions are expected only after those patents lapse, probably in the mid‑2030s.

Why the patents are still in force

These dates are approximate, based on the “first‑to‑file” filing dates and the standard 20‑year term from filing. Some patents may be extended by Patent Term Extensions (PTE) or Patent Term Adjustments (PTA) granted by the USPTO for regulatory delays.

Because the U.S. and EU patents all have expiry dates in the 2030s, Mounjaro remains a brand‑name, patented product for the foreseeable future.

What does that mean for patients and prescribers?

1. No generics yet – Until the patents expire (or are challenged successfully), the only legally available form in the U.S. is Mounjaro from Eli Lilly.
2. Pricing & insurance – The brand status usually keeps prices higher, though insurers may negotiate rebates.
3. Patent litigation – Eli Lilly has a history of defending its patents aggressively. If a generic company files a “Paragraph IV” challenge, the outcome is uncertain until a court ruling.

Where to find the official status

• USPTO Patent Full‑Text and Image Database (PatFT) – Search for “tirzepatide” or Eli Lilly’s assignee.
• European Patent Register – Look up the EP numbers above.
• FDA’s Orange Book – Lists approved drug products and their exclusivity periods.
• Eli Lilly’s corporate disclosures – Often summarize the key patents in investor relations materials.

Bottom line

Mounjaro’s patents are not ended—generics will not enter the market until at least the early‑mid 2030s. If you’re a prescriber, keep an eye on FDA announcements and patent court decisions, but for now the brand remains protected.